<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Additionally, despite conflicting advice from the US Food and Drug Administration,
 <xref rid="bib65" ref-type="bibr">
  <sup>65</sup>
 </xref> the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, was thought to be likely to result in an induction of increased ACE2 receptors.
 <xref rid="bib66" ref-type="bibr">
  <sup>66</sup>
 </xref> For critically ill adults with COVID-19 who develop fever, acetaminophen might be a better choice for temperature control than NSAIDs.
 <xref rid="bib67" ref-type="bibr">
  <sup>67</sup>
 </xref> Of note, according to a study by Wu et al. (2020), treatment of COVID-19 patients with methylprednisolone was shown to decrease the case-fatality risk (HR, 0.38; 95% CI, 0.20–0.72).
 <xref rid="bib68" ref-type="bibr">
  <sup>68</sup>
 </xref> However, the administered dose of methylprednisolone is not specified in that investigation. Despite a lack of supporting evidence, some critical care experts advocate the use of low-dose corticosteroid therapy in adults with COVID-19 and refractory shock (e.g., intravenous hydrocortisone 200 mg per day, as a “shock-reversal” strategy).
 <xref rid="bib68" ref-type="bibr">
  <sup>68</sup>
 </xref>
</p>
